{"title":"MiR-568-5p是冠状动脉疾病中细胞因子信号传导4 (SOCS4)抑制因子的关键调节因子。","authors":"Tayebeh Sadeghi, Majid Zaki-Dizaji, Meisam Rostaminasab Dolatabad, Zahra Taheri","doi":"10.1007/s40200-025-01619-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Pro-inflammatory molecules are key risk factors for coronary artery diseases (CAD). Therefore, the regulation of inflammatory responses plays a crucial role in CAD. Suppressor of cytokine signaling 4 (SOCS4) is a negative regulator of cytokine signaling may significantly contribute to the pathogenesis of CAD. Bioinformatics studies indicate that hsa-miR-568-5p can target SOCS4. This study aimed to evaluate the expression of hsa-miR-568-5p in patients with CAD and investigate its correlation with SOCS4 levels.</p><p><strong>Methods: </strong>The study included 20 Iranian participants without artery stenosis and 40 with artery stenosis. The relative expression levels of hsa-miR-568-5p and SOCS4 were assessed using Real-Time PCR.</p><p><strong>Results: </strong>The findings revealed no significant difference in the expression levels of hsa-miR-568-5p and SOCS4 between the two groups. Also, correlations were not observed between hsa-miR-568-5p, SOCS4, and age in both the control and CAD patient groups.</p><p><strong>Conclusions: </strong>While hsa-miR-568-5p regulates SOCS4 expression, and SOCS4 upregulation is implicated in coronary artery disease (CAD) protection, this study found no conclusive evidence supporting this relationship. Further research is warranted.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"106"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014962/pdf/","citationCount":"0","resultStr":"{\"title\":\"MiR-568-5p, the key regulator of suppressor of cytokine signaling 4 (SOCS4) in the coronary artery disease.\",\"authors\":\"Tayebeh Sadeghi, Majid Zaki-Dizaji, Meisam Rostaminasab Dolatabad, Zahra Taheri\",\"doi\":\"10.1007/s40200-025-01619-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Pro-inflammatory molecules are key risk factors for coronary artery diseases (CAD). Therefore, the regulation of inflammatory responses plays a crucial role in CAD. Suppressor of cytokine signaling 4 (SOCS4) is a negative regulator of cytokine signaling may significantly contribute to the pathogenesis of CAD. Bioinformatics studies indicate that hsa-miR-568-5p can target SOCS4. This study aimed to evaluate the expression of hsa-miR-568-5p in patients with CAD and investigate its correlation with SOCS4 levels.</p><p><strong>Methods: </strong>The study included 20 Iranian participants without artery stenosis and 40 with artery stenosis. The relative expression levels of hsa-miR-568-5p and SOCS4 were assessed using Real-Time PCR.</p><p><strong>Results: </strong>The findings revealed no significant difference in the expression levels of hsa-miR-568-5p and SOCS4 between the two groups. Also, correlations were not observed between hsa-miR-568-5p, SOCS4, and age in both the control and CAD patient groups.</p><p><strong>Conclusions: </strong>While hsa-miR-568-5p regulates SOCS4 expression, and SOCS4 upregulation is implicated in coronary artery disease (CAD) protection, this study found no conclusive evidence supporting this relationship. Further research is warranted.</p>\",\"PeriodicalId\":15635,\"journal\":{\"name\":\"Journal of Diabetes and Metabolic Disorders\",\"volume\":\"24 1\",\"pages\":\"106\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014962/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes and Metabolic Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40200-025-01619-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Metabolic Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40200-025-01619-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
MiR-568-5p, the key regulator of suppressor of cytokine signaling 4 (SOCS4) in the coronary artery disease.
Objectives: Pro-inflammatory molecules are key risk factors for coronary artery diseases (CAD). Therefore, the regulation of inflammatory responses plays a crucial role in CAD. Suppressor of cytokine signaling 4 (SOCS4) is a negative regulator of cytokine signaling may significantly contribute to the pathogenesis of CAD. Bioinformatics studies indicate that hsa-miR-568-5p can target SOCS4. This study aimed to evaluate the expression of hsa-miR-568-5p in patients with CAD and investigate its correlation with SOCS4 levels.
Methods: The study included 20 Iranian participants without artery stenosis and 40 with artery stenosis. The relative expression levels of hsa-miR-568-5p and SOCS4 were assessed using Real-Time PCR.
Results: The findings revealed no significant difference in the expression levels of hsa-miR-568-5p and SOCS4 between the two groups. Also, correlations were not observed between hsa-miR-568-5p, SOCS4, and age in both the control and CAD patient groups.
Conclusions: While hsa-miR-568-5p regulates SOCS4 expression, and SOCS4 upregulation is implicated in coronary artery disease (CAD) protection, this study found no conclusive evidence supporting this relationship. Further research is warranted.
期刊介绍:
Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of endocrinology and provides a forum of debate of the highest quality on these issues. Topics of interest include, but are not limited to, diabetes, lipid disorders, metabolic disorders, osteoporosis, interdisciplinary practices in endocrinology, cardiovascular and metabolic risk, aging research, obesity, traditional medicine, pychosomatic research, behavioral medicine, ethics and evidence-based practices.As of Jan 2018 the journal is published by Springer as a hybrid journal with no article processing charges. All articles published before 2018 are available free of charge on springerlink.Unofficial 2017 2-year Impact Factor: 1.816.